-+ 0.00%
-+ 0.00%
-+ 0.00%

Lakewood-Amedex taps PERI as CRO for Nu-3 Phase 2 diabetic foot ulcer trial

PUBT·05/12/2026 12:04:44
Listen to the news
Lakewood-Amedex taps PERI as CRO for Nu-3 Phase 2 diabetic foot ulcer trial
  • Lakewood-Amedex Biotherapeutics entered agreement with Professional Education and Research Institute (PERI) to act as contract research organization for upcoming Phase 2 clinical program of Nu-3 in mildly infected diabetic foot ulcers.
  • Partnership targets Phase 2a single-blinded study comparing 2%, 5%, 10% Nu-3 gel concentrations, followed by Phase 2b testing once-daily or twice-daily dosing versus placebo.
  • Collaboration positions PERI’s wound-care investigator network to support site access, patient recruitment, data generation as Nu-3 advances toward potential registration pathway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605120802PR_NEWS_USPR_____NY56570) on May 12, 2026, and is solely responsible for the information contained therein.